Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many…
– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose –…
JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today…
REDDING, Calif., Sept. 24, 2024 /PRNewswire/ -- According to a new market research report titled, 'Genomics Market Size, Share, Forecast, &…
The Healthcare Software as a Service (SaaS) market is primarily driven by the increasing demand for cost-effective and scalable solutions…
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept.…
New Zeki Data Report Breaks Down Competition Within the Deep-Tech Ecosystem LONDON, Sept. 24, 2024 /PRNewswire/ -- A new global…
CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…
CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for…